The TDR Three Key Takeaways regarding MindBio Therapeutics Corp. Phase 2B Trials with MB22001: MindBio highlights progress in Phase 2B trials for MB22001, targeting major
The TDR Three Key Takeaways regarding MindBio Therapeutics and MB22001 Early trials indicate MB22001 could offer an alternative to traditional antidepressants Hanka stresses MB22001’s impact
The TDR Three Key Takeaways regarding Psychedelics and Stutterers: Initial studies suggest psychedelics might help stutterers by altering brain function. Psychedelics have been shown to
The TDR Three Key Takeaways regarding Psychedelic therapies and Zappy Zapolin: Zappy Zapolin uses documentaries to advocate for psychedelic medicine’s benefits. Insurance companies’ interest could
The TDR Three Key Takeaways regarding atai Life Sciences Q1 2024 Earnings Report: atai Life Sciences reports a net loss of $26.7 million for Q1
The TDR Three Key Takeaways regarding Psychedelics and MindBio Therapeutics: MindBio and Enveric collaborate on new psychedelics. MindBio helps develop patient-friendly psychedelic options. MindBio’s efforts
The TDR Three Key Takeaways regarding AbbVie and Gilgamesh: Gilgamesh and AbbVie join forces to tackle innovative mental health therapies. Gilgamesh could earn up to
The TDR Three Key Takeaways regarding Numinus Wellness Numinus unveils a strategy to focus on profitable U.S. operations. This announcement follows other significant announcements of
The TDR Three Key Takeaways regarding MindBio and Women’s Health: MindBio initiates Phase 2B trials targeting PMS and PMDD treatment. Home administration of MB22001 revolutionizes
The TDR Three Key Takeaways regarding NIH Initiative on Psychedelic Therapy: Federal backing of psychedelic research marks a shift in policy. NIH to conduct extensive